drugset / Trial / NCT00472056
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
RandomizedParallel-groupOpen-labelTreatment
Summary
Cohort 1: Patients who are less than or equal to 65 years of age. 1\. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) Cohort 2: Patients who are older than 65 years of age 1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) 2. To determine the treatment related mortality (TRM)
Timeline
- Start
- 2005-03
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 200 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Etoposide | Small molecule | 200 mg/m2 | — |
| Subject | Melphalan | Small molecule | 140 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1000 mg/m2 | Intravenous |
| Subject | carmustine | Small molecule | 300 mg/m2 | — |